[Osteoporosis and bisphosphonates].
作者信息
Zuber M A
机构信息
Klinik für Rheumatologie der Universität Magdeburg, Fachkrankenhaus Vogelsang, Sophie-von-Bötticher-Strasse 1, 39245, Gommern, Germany.
出版信息
Z Rheumatol. 2007 Dec;66(8):713-5. doi: 10.1007/s00393-007-0227-8.
PMID:17955251
Abstract
摘要
相似文献
1
[Osteoporosis and bisphosphonates].
Z Rheumatol. 2007 Dec;66(8):713-5. doi: 10.1007/s00393-007-0227-8.
2
[Atrial fibrillation during bisphosphonate therapy. side effects or coincidental finding?].
MMW Fortschr Med. 2009 Mar 5;151(10):7.
3
Bisphosphonates and atrial fibrillation.
Prescrire Int. 2008 Aug;17(96):161.
4
Zoledronic acid: new indication. No therapeutic advantage in postmenopausal osteoporosis.
Prescrire Int. 2008 Aug;17(96):143.
5
Annual zoledronic acid for osteoporosis.
Drug Ther Bull. 2008 Dec;46(12):93-6.
6
Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
Ann Pharmacother. 2008 Jul;42(7):1085-9. doi: 10.1345/aph.1K652. Epub 2008 May 27.
7
[Treating with what? Therapy for how long?].
MMW Fortschr Med. 2005 Dec 15;147(51-52):62-3.
8
A once-yearly IV bisphosphonate for osteoporosis.
Med Lett Drugs Ther. 2007 Nov 5;49(1273):89-90.
9
Yearly zoledronic acid in postmenopausal osteoporosis.
N Engl J Med. 2007 Aug 16;357(7):712-3; author reply 714-5.
10
A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis.
Bone. 2009 Jun;44(6):1078-84. doi: 10.1016/j.bone.2009.02.016. Epub 2009 Mar 2.
Zotero 插件